Novartis's Zelnorm Enters Restricted Access Program
A few months after the U.S. Food and Drug Administration ordered it pulled from the market amid concerns about causing heart problems, Novartis AG's controversial drug Zelnorm will return under a...To view the full article, register now.
Already a subscriber? Click here to view full article